Knight Capital Group’s Ionis Pharmaceuticals IONS Stock Holding History

Knight Capital Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$924K	Buy	+34,396	New	+$731K	0.02%	1091

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Knight Capital Group's IONS Position: Q2 2013 in Review

Knight Capital Group opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2013: 34,396 shares worth $924K. The stake represents 0.02% of the portfolio and ranks #1091 among its holdings.

173 funds tracked by Wall St. Rank hold IONS as of Q2 2013.

Knight Capital Group held 34,396 shares of Ionis Pharmaceuticals worth $924K as of Q2 2013.
Ionis Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
Ionis Pharmaceuticals made up 0.02% of Knight Capital Group's portfolio in Q2 2013, its #1091 holding.
173 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.